February 14, 2014
Nichi-Iko Pharmaceutical has made up its mind to venture into the US market – possibly in 2018 with the launch of its biosimilar version of the rheumatoid arthritis drug Remicade (infliximab). The major Japanese generic and biosimilar maker said on...read more